TransMedics Group, Inc. raised revenue guidance for the full year 2024. For the period, the company expects revenue to be in the range of $390 million to $400 million, which represents 61% to 66% growth compared to the company's prior year revenue. Company's prior 2024 revenue guidance was $360 million to $370 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
142 USD | -0.97% | +3.52% | +79.92% |
Jun. 07 | CL King Initiates TransMedics at Buy Rating With $161 Price Target | MT |
Jun. 05 | Transmedics Group Insider Sold Shares Worth $393,986, According to a Recent SEC Filing | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+79.92% | 4.68B | |
+7.77% | 218B | |
+10.16% | 189B | |
+26.21% | 151B | |
+32.78% | 113B | |
+1.14% | 64.02B | |
+14.48% | 52.6B | |
+2.92% | 49.85B | |
-6.60% | 37.89B | |
-1.07% | 34.92B |
- Stock Market
- Equities
- TMDX Stock
- News TransMedics Group, Inc.
- TransMedics Group, Inc. Raises Revenue Guidance for the Full Year 2024